Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences Co., Ltd. has announced that its board of directors will meet on October 28, 2025, to review and approve the company’s unaudited financial results for the nine months ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and performance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company based in the People’s Republic of China, operating in the biosciences industry. The company focuses on the development and commercialization of innovative therapies, contributing to advancements in healthcare and pharmaceuticals.
Average Trading Volume: 12,070,146
Technical Sentiment Signal: Buy
Current Market Cap: HK$39.53B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.